GlassScriptPhysician profile
Virginia Wohltmann
NPI 1740332915
$6,129.79
in general payments reported to CMS, 2019-2025
19 companies · $2,224 in 2025
The $2,224 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $125 · 2021: $344 · 2022: $711 · 2023: $906 · 2024: $1,602 · 2025: $2,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,414 · Education: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,413.67 |
| Education | $317.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,085.26 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $806.49 | 2019-2025 | Invega Sustenna |
| Abbvie INC. | $640.83 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $585.49 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $516.71 | 2022-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $516.58 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $462.49 | 2019-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $420.13 | 2024-2025 | Cobenfy |
| Corium, LLC | $304.73 | 2022-2025 | Azstarys |
| Indivior INC. | $276.45 | 2022-2024 | Perseris, Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.58 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $77.38 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $66.33 | 2020-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $52.92 | 2023-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $39.41 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $26.36 | 2021 | |
| Sunovion Pharmaceuticals INC. | $19.07 | 2019 | |
| Noven Therapeutics, LLC | $17.47 | 2024 | Xelstrym, Secuado |
| Allergan, INC. | $14.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Wohltmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.